Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature

European Urology

Volumn 68, Issue 2, 2015, Pages 238-253

  Kluth, Luis A ^a,b   Black, Peter C ^c   Bochner, Bernard H ^d   Catto, James ^e   Lerner, Seth P ^f   Stenzl, Arnulf ^g   Sylvester, Richard ^h   Vickers, Andrew J ^d   Xylinas, Evanguelos ^a,i   Shariat, Shahrokh F ^a,j,k  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h EORTC DATA CENTER   (Belgium)

ⁱ Institut Cochin   (France)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

Bladder cancer; Disease recurrence; Nomogram; Outcome; Prediction; Prediction tool; Prognosis; Prognostic tool; Radical cystectomy; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADJUVANT THERAPY; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COUNSELING; CYSTECTOMY; DISEASE FREE SURVIVAL; HUMAN; LITERATURE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; META ANALYSIS (TOPIC); METASTASIS; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PELVIS LYMPH NODE; PEROPERATIVE COMPLICATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; DECISION SUPPORT SYSTEM; DISEASE COURSE; METABOLISM; MORTALITY; NOMOGRAM; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS;

BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84937513403     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.01.032     Document Type: Review

References (106)

1. M. Burger, J.W. Catto, G. Dalbagni, and et al. Epidemiology and risk factors of urothelial bladder cancer Eur Urol 63 2013 234 241
2. M. Burger, W. Oosterlinck, B. Konety, and et al. ICUD-EAU International Consultation on Bladder Cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder Eur Urol 63 2013 36 44
3. M. Babjuk, M. Burger, R. Zigeuner, and et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013 Eur Urol 64 2013 639 653
4. P.L. Ross, C. Gerigk, M. Gonen, and et al. Comparisons of nomograms and urologists' predictions in prostate cancer Semin Urol Oncol 20 2002 82 88
5. M.C. Specht, M.W. Kattan, M. Gonen, and et al. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram Ann Surg Oncol 12 2005 654 659
6. S.B. Edge, and C.C. Compton The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM Ann Surg Oncol 17 2010 1471 1474
7. R.J. Sylvester, A.P. van der Meijden, W. Oosterlinck, and et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 475 discussion 475-7
8. P.I. Karakiewicz, S.F. Shariat, G.S. Palapattu, and et al. Precystectomy nomogram for prediction of advanced bladder cancer stage Eur Urol 50 2006 1254 1260 discussion 1261-2
9. J.W. Catto, M.F. Abbod, D.A. Linkens, and et al. Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder Clin Cancer Res 15 2009 3150 3155
10. K. Chamie, C.S. Saigal, J. Lai, and et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care Cancer 117 2011 5392 5401
11. R.J. Sylvester, W. Oosterlinck, and A.P. van der Meijden A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials J Urol 171 2004 2186 2190 quiz 2435
12. J.J. Meeks, J. Bellmunt, B.H. Bochner, and et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer Eur Urol 62 2012 523 533
13. M.K. Parmar, L.S. Freedman, T.B. Hargreave, and et al. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party) J Urol 142 1989 284 288
14. K.N. Qureshi, R.N. Naguib, F.C. Hamdy, and et al. Neural network analysis of clinicopathological and molecular markers in bladder cancer J Urol 163 2000 630 633
15. F. Millan-Rodriguez, G. Chechile-Toniolo, J. Salvador-Bayarri, and et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence J Urol 164 2000 680 684
16. J.W. Catto, D.A. Linkens, M.F. Abbod, and et al. Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks Clin Cancer Res 9 2003 4172 4177
17. K. Fujikawa, Y. Matsui, T. Kobayashi, and et al. Predicting disease outcome of non-invasive transitional cell carcinoma of the urinary bladder using an artificial neural network model: results of patient follow-up for 15 years or longer Int J Urol 10 2003 149 152
18. S.F. Shariat, C. Zippe, G. Ludecke, and et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder J Urol 173 2005 1518 1525
19. J.W. Catto, M.F. Abbod, D.A. Linkens, and et al. Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression J Urol 175 2006 474 479
20. S.J. Hong, K.S. Cho, M. Han, and et al. Nomograms for prediction of disease recurrence in patients with primary Ta, T1 transitional cell carcinoma of the bladder J Korean Med Sci 23 2008 428 433
21. J. Fernandez-Gomez, R. Madero, E. Solsona, and et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model J Urol 182 2009 2195 2203
22. C.C. Pan, Y.H. Chang, K.K. Chen, and et al. Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder J Clin Pathol 63 2010 910 915
23. T. Yamada, K. Tsuchiya, S. Kato, and et al. A pretreatment nomogram predicting recurrence- and progression-free survival for nonmuscle invasive bladder cancer in Japanese patients Int J Clin Oncol 15 2010 271 279
24. B. Ali-El-Dein, P. Sooriakumaran, Q.D. Trinh, and et al. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre BJU Int 111 2013 E331 E341
25. V. Hernandez, E. De La Pena, M.D. Martin, and et al. External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer World J Urol 29 2011 409 414
26. S. Sakano, H. Matsuyama, K. Takai, and et al. Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European Association of Urology guidelines BJU Int 107 2011 1598 1604
27. K.W. Seo, B.H. Kim, C.H. Park, and et al. The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical bacillus calmette-guerin instillation Korean J Urol 51 2010 165 170
28. B.W.G. van Rhijn, T.C.M. Zuiverloon, A.N. Vis, and et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer Eur Urol 58 2010 433 441
29. R. Pillai, D. Wang, E.K. Mayer, and et al. Do standardised prognostic algorithms reflect local practice? Application of EORTC risk tables for non-muscle invasive (pTa/pT1) bladder cancer recurrence and progression in a local cohort ScientificWorldJournal 11 2011 751 759
30. J. Fernandez-Gomez, R. Madero, E. Solsona, and et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables Eur Urol 60 2011 423 430
31. H.M. Rosevear, A.J. Lightfoot, K.G. Nepple, and et al. Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guerin plus interferon-alpha J Urol 185 2011 67 71
32. E. Xylinas, M. Kent, L. Kluth, and et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder Br J Cancer 109 2013 1460 1466
33. R.J. Lammers, R.J. Sylvester, C.T. Lee, and et al. NMIBC risk calculators: how useful are they for the practicing urologist and how can their clinical utility be improved? Urol Clin North Am 40 2013 155 164
34. F. Koga, S. Kobayashi, Y. Fujii, and et al. Significance of positive urine cytology on progression and cancer-specific mortality of non - muscle-invasive bladder cancer Clin Genitourin Cancer 12 2014 e87 e93
35. D. Margel, A. Harel, O. Yossepowitch, and et al. A novel algorithm to improve pathologic stage prediction of clinically organ-confined muscle-invasive bladder cancer Cancer 115 2009 1459 1464
36. H.Y. Xie, Y. Zhu, X.D. Yao, and et al. Development of a nomogram to predict non-organ-confined bladder urothelial cancer before radical cystectomy Int Urol Nephrol 44 2012 1711 1719
37. D.A. Green, M. Rink, J. Hansen, and et al. Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy BJU Int 111 2013 404 411
38. A.P. Mitra, E.C. Skinner, G. Miranda, and et al. A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer BJU Int 111 2013 240 248
39. H. Ahmadi, A.P. Mitra, G.A. Abdelsayed, and et al. Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer BJU Int 111 2013 E167 E172
40. S.F. Shariat, G.S. Palapattu, P.I. Karakiewicz, and et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy Eur Urol 51 2007 137 149 discussion 149-51
41. H.B. Grossman, R.B. Natale, C.M. Tangen, and et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866
42. G. Griffiths, R. Hall, R. Sylvester, and et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2011 2171 2177
43. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data Eur Urol 48 2005 202 205 discussion 205-6
44. R. Takata, T. Katagiri, M. Kanehira, and et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling Clin Cancer Res 11 2005 2625 2636
45. R. Takata, W. Obara, and T. Fujioka Study of the prediction system for clinical response to M-VAC neoadjuvant chemotherapy for bladder cancer Aktuelle Urol 41 Suppl 1 2010 S41 S45
46. S.C. Smith, A.S. Baras, G. Dancik, and et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment Lancet Oncol 12 2011 137 143
47. S.F. Shariat, B. Ehdaie, M. Rink, and et al. Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment Eur Urol 61 2012 237 242
48. S.F. Shariat, M. Rink, B. Ehdaie, and et al. Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy Eur Urol 63 2013 371 378
49. P.I. Karakiewicz, S.F. Shariat, G.S. Palapattu, and et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder J Urol 176 2006 1354 1361 discussion 1361-2
50. S.F. Shariat, P.I. Karakiewicz, G.S. Palapattu, and et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy Clin Cancer Res 12 2006 6663 6676
51. U. Capitanio, N. Suardi, S.F. Shariat, and et al. Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer BJU Int 103 2009 1359 1362
52. G. Dancik, D. Aisner, and D. Theodorescu A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors PLoS Curr 3 2011 RRN1248
53. J. Leissner, M.A. Ghoneim, H. Abol-Enein, and et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study J Urol 171 2004 139 144
54. M. May, E. Herrmann, C. Bolenz, and et al. Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy Ann Surg Oncol 18 2011 2018 2025
55. H. Isbarn, C. Jeldres, L. Zini, and et al. A population based assessment of perioperative mortality after cystectomy for bladder cancer J Urol 182 2009 70 77
56. T.M. Morgan, K.A. Keegan, D.A. Barocas, and et al. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy J Urol 186 2011 829 834
57. F. Abdollah, M. Sun, J. Schmitges, and et al. Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study Ann Surg Oncol 19 2012 309 317
58. E. Solsona, I. Iborra, R. Dumont, and et al. Risk groups in patients with bladder cancer treated with radical cystectomy: statistical and clinical model improving homogeneity J Urol 174 2005 1226 1230
59. B.H. Bochner, M.W. Kattan, and K.C. Vora Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer J Clin Oncol 24 2006 3967 3972
60. P. Bassi, E. Sacco, V. De Marco, and et al. Prognostic accuracy of an artificial neural network in patients undergoing radical cystectomy for bladder cancer: a comparison with logistic regression analysis BJU Int 99 2007 1007 1012
61. S.F. Shariat, P.I. Karakiewicz, R. Ashfaq, and et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy Cancer 112 2008 315 325
62. S.F. Shariat, C. Bolenz, G. Godoy, and et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy J Urol 182 2009 78 84
63. A.P. Mitra, V. Pagliarulo, D. Yang, and et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer J Clin Oncol 27 2009 3929 3937
64. E.C. Umbreit, P.L. Crispen, M.S. Shimko, and et al. Multifactorial, site-specific recurrence model after radical cystectomy for urothelial carcinoma Cancer 116 2010 3399 3407
65. S.F. Shariat, D.C. Chade, P.I. Karakiewicz, and et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer J Urol 183 2010 68 75
66. G. Sonpavde, M.M. Khan, R.S. Svatek, and et al. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy BJU Int 108 2011 687 692
67. G. Sonpavde, M.M. Khan, R.S. Svatek, and et al. Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy J Urol 185 2011 1216 1221
68. Y. Kim, T.K. Kim, Y. Kim, and et al. Principal network analysis: identification of subnetworks representing major dynamics using gene expression data Bioinformatics 27 2011 391 398
69. G. Gakis, T. Todenhofer, M. Renninger, and et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score BJU Int 108 2011 1800 1805
70. T. Todenhöfer, M. Renninger, C. Schwentner, and et al. A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors BJU Int 110 2012 E533 E540
71. F. Koga, Y. Fujii, H. Masuda, and et al. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches BJU Int 110 2012 E203 E208
72. T. Gondo, J. Nakashima, C. Ozu, and et al. Risk stratification of survival by lymphovascular invasion, pathological stage, and surgical margin in patients with bladder cancer treated with radical cystectomy Int J Clin Oncol 17 2012 456 461
73. J. Ishioka, K. Saito, M. Sakura, and et al. Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis Br J Cancer 107 2012 1031 1036
74. M. Riester, J.M. Taylor, A. Feifer, and et al. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer Clin Cancer Res 18 2012 1323 1333
75. S.F. Shariat, T.F. Chromecki, E.K. Cha, and et al. Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers J Urol 187 2012 457 462
76. E. Xylinas, E.K. Cha, M. Sun, and et al. Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling Br J Cancer 107 2012 1826 1832
77. Rink M, Hansen J, Cha EK, et al. Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. BJU Int 2013; 111:74-84.
78. A. Buchner, M. May, M. Burger, and et al. Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networks Eur J Surg Oncol 39 2013 372 379
79. Y. Lotan, A. Bagrodia, N. Passoni, and et al. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy Eur Urol 64 2013 465 471
80. M.S. Eisenberg, S.A. Boorjian, J.C. Cheville, and et al. The SPARC score: a multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer J Urol 190 2013 2005 2010
81. B.C. Baumann, T.J. Guzzo, J. He, and et al. A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy Int J Radiat Oncol Biol Phys 85 2013 81 88
82. T. Sejima, S. Morizane, A. Yao, and et al. Prognostic impact of preoperative hematological disorders and a risk stratification model in bladder cancer patients treated with radical cystectomy Int J Urol 21 2014 52 57
83. A.J. Vickers, and E.B. Elkin Decision curve analysis: a novel method for evaluating prediction models Med Decis Making 26 2006 565 574
84. A.J. Vickers, A.M. Cronin, M.W. Kattan, and et al. Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach Cancer 115 2009 5460 5469
85. G. Ploussard, S.F. Shariat, A. Dragomir, and et al. Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time Eur Urol 66 2014 361 370
86. J.A. Karam, Y. Lotan, P.I. Karakiewicz, and et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy Lancet Oncol 8 2007 128 136
87. L.C. Wang, E. Xylinas, M.T. Kent, and et al. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder Urol Oncol 32 2014 433 440
88. A. Stenzl, N.C. Cowan, M. De Santis, and et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines Eur Urol 59 2011 1009 1018
89. J.P. Stein, G. Lieskovsky, R. Cote, and et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 2001 666 675
90. S.F. Shariat, P.I. Karakiewicz, G.S. Palapattu, and et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium J Urol 176 2006 2414 2422 discussion 2422
91. S. Madersbacher, W. Hochreiter, F. Burkhard, and et al. Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy J Clin Oncol 21 2003 690 696
92. D.F. Bajorin, P.M. Dodd, M. Mazumdar, and et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy J Clin Oncol 17 1999 3173 3181
93. J. Bellmunt, H. von der Maase, G.M. Mead, and et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987 J Clin Oncol 30 2012 1107 1113
94. R. Mayr, M. May, T. Martini, and et al. Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder Eur Urol 62 2012 662 670
95. T. Nakagawa, T. Hara, T. Kawahara, and et al. Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy J Urol 189 2013 1275 1281
96. M. Ploeg, A.C. Kums, K.K. Aben, and et al. Prognostic factors for survival in patients with recurrence of muscle invasive bladder cancer after treatment with curative intent Clin Genitourin Cancer 9 2011 14 21
97. M. De Santis, J. Bellmunt, G. Mead, and et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II - results of EORTC study 30986 J Clin Oncol 27 2009 5634 5639
98. A.B. Apolo, I. Ostrovnaya, S. Halabi, and et al. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy J Natl Cancer Inst 105 2013 499 503
99. J. Gibbs, W. Cull, W. Henderson, and et al. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study Arch Surg 134 1999 36 42
100. J.R. Gregg, M.S. Cookson, S. Phillips, and et al. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer J Urol 185 2011 90 96
101. J. Bellmunt, T.K. Choueiri, R. Fougeray, and et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens J Clin Oncol 28 2010 1850 1855
102. G. Niegisch, R. Fimmers, R. Siener, and et al. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99) Eur Urol 60 2011 1087 1096
103. L.A. Kluth, E. Xylinas, M. Rieken, and et al. Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder BJU Int 113 2014 393 398
104. M.D. Galsky, E. Moshier, S. Krege, and et al. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy Cancer 119 2013 3012 3019
105. D.A. Green, M. Rink, E. Xylinas, and et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins J Urol 189 2013 1214 1221
106. Kluth LA, Xylinas E, Rieken M, et al. Prognostic model for predicting survival in patients with disease recurrence following radical cystectomy. Eur Urol Focus. In press. http://dx.doi.org/10.1016/j.euf.2014.10.003